Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
Recruiting · NCT05751733 · Registry updated 2023-03-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, neoplasm | Recruiting | Not applicable | 2023-03-02 | NCT05751733 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 74 |
| Xiangya Hospital of Central South University | 162 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Xiangya Hospital, Central South University | Changsha | China | 2 |